DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice

Journal of Virological Methods

Volumn 206, Issue , 2014, Pages 12-18

  Bahrami, Armina Alagheband ^a   Ghaemi, Amir ^a,b   Tabarraei, Alijan ^a   Sajadian, Azadeh ^b   Gorji, Ali ^b,c   Soleimanjahi, Hoorieh ^d  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Shefa Neuroscience Research Center   (Iran)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Cervical cancer; DNA vaccines; E7; Human papilloma virus; Mutant; PRb binding motif

Indexed keywords

CYSTEINE; DNA VACCINE; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 4; LEUCINE; LYMPHOTOXIN; PROTEIN E7; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; WART VIRUS VACCINE; CYTOKINE; MUTANT PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN BINDING; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL IMMORTALIZATION; CELL TRANSFORMATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG DESIGN; E7 GENE; FEMALE; GENE; GENE MUTATION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; UPREGULATION; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VIRAL GENE THERAPY; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROTEIN MOTIF; SECRETION (PROCESS);

AMINO ACID MOTIFS; ANIMALS; BINDING SITES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE, INBRED C57BL; MUTANT PROTEINS; NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 84902097427     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.05.013     Document Type: Article

References (37)

1. Achyut B.R., Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011, 141:1167-1178.
2. Barbosa M.S., Edmonds C., Fisher C., Schiller J.T., Lowy D.R., Vousden K.H. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 1990, 9:153-160.
3. Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., Smith L.R., Kast W.M. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22:520-527.
4. Chen S., Liao C., Lai Y., Fan Y., Lu G., Wang H., Zhang X., Lin M.C., Leng S., Kung H.F. De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin. Acta Biochim. Biophys. Sin. 2014, 46:6-14.
5. Comerford S.A., McCance D.J., Dougan G., Tite J.P. Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. J. Virol. 1991, 65:4681-4690.
6. Cubie H.A. Diseases associated with human papillomavirus infection. Virology 2013, 445:21-34.
7. Eiben G.L., da Silva D.M., Fausch S.C., Le Poole I.C., Nishimura M.I., Kast W.M. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003, 16:111-121.
8. Elfstrom K.M., Herweijer E., Sundstrom K., Arnheim-Dahlstrom L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review. Curr. Opin. Oncol. 2014, 26:120-129.
9. Ghaemi A., Soleimanjahi H., Gill P., Hassan Z., Jahromi S.R., Roohvand F. Recombinant lambda-phage nanobioparticles for tumor therapy in mice models. Genet. Vaccines Ther. 2010, 8:3.
10. Ghaemi A., Soleimanjahi H., Gill P., Hassan Z.M., Razeghi S., Fazeli M., Razavinikoo S.M. Protection of mice by a lambda-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology 2011, 54:105-112.
11. Ghittoni R., Accardi R., Hasan U., Gheit T., Sylla B., Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40:1-13.
12. Grasso F., Negri D.R., Mochi S., Rossi A., Cesolini A., Giovannelli A., Chiantore M.V., Leone P., Giorgi C., Cara A. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Int. J. Cancer 2013, 132:335-344.
13. Hung C.F., Monie A., Alvarez R.D., Wu T.C. DNA vaccines for cervical cancer: from bench to bedside. Exp. Mol. Med. 2007, 39:679-689.
14. Jones R.E., Heimbrook D.C., Huber H.E., Wegrzyn R.J., Rotberg N.S., Stauffer K.J., Lumma P.K., Garsky V.M., Oliff A. Specific N-methylations of HPV-16 E7 peptides alter binding to the retinoblastoma suppressor protein. J. Biol. Chem. 1992, 267:908-912.
15. Jones R.E., Wegrzyn R.J., Patrick D.R., Balishin N.L., Vuocolo G.A., Riemen M.W., Defeo-Jones D., Garsky V.M., Heimbrook D.C., Oliff A. Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J. Biol. Chem. 1990, 265:12782-12785.
16. Ledl A., Schmidt D., Muller S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 2005, 24:3810-3818.
17. Li H., Ou X., Xiong J. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Gynecol. Oncol. 2007, 104:564-571.
18. Li L., Saade F., Petrovsky N. The future of human DNA vaccines. J. Biotechnol. 2012, 162:171-182.
19. Lopez M., Aguilera R., Perez C., Mendoza-Naranjo A., Pereda C., Ramirez M., Ferrada C., Aguillon J.C., Salazar-Onfray F. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. Immunobiology 2006, 211:127-136.
20. Moniz M., Ling M., Hung C.F., Wu T.C. HPV DNA vaccines. Front. Biosci. 2003, 8:d55-d68.
21. Morrow M.P., Yan J., Sardesai N.Y. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Exp. Rev. Vaccines 2013, 12:271-283.
22. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898.
23. Narechania A., Terai M., Chen Z., DeSalle R., Burk R.D. Lack of the canonical pRB-binding domain in the E7 ORF of artiodactyl papillomaviruses is associated with the development of fibropapillomas. J. Gen. Virol. 2004, 85:1243-1250.
24. Ohlschlager P., Pes M., Osen W., Durst M., Schneider A., Gissmann L., Kaufmann A.M. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006, 24:2880-2893.
25. Pang C.L., Toh S.Y., He P., Teissier S., Ben Khalifa Y., Xue Y., Thierry F. A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes. (129 c). Oncogene 2013, 10.1038/onc.2013.426.
26. Peng S., Tomson T.T., Trimble C., He L., Hung C.F., Wu T.C. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. 2006, 13:257-265.
27. Radaelli A., De Giuli Morghen C., Zanotto C., Pacchioni S., Bissa M., Franconi R., Massa S., Paolini F., Muller A., Venuti A. A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers. Virus Res. 2012, 170:44-52.
28. Santana V.C., Diniz M.O., Cariri F.A., Ventura A.M., Cunha-Neto E., Almeida R.R., Campos M.A., Lima G.K., Ferreira L.C. Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8(+) T cell responses and protective immunity. PLoS ONE 2013, 8:e71322.
29. Sasagawa T., Takagi H., Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J. Infect. Chemother. 2012, 18:807-815.
30. Shi W., Bu P., Liu J., Polack A., Fisher S., Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol. 1999, 73:7877-7881.
31. Singh M., Krajewski M., Mikolajka A., Holak T.A. Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J. Biol. Chem. 2005, 280:37868-37876.
32. Smahel M., Sima P., Ludvikova V., Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001, 281:231-238.
33. Tomson T.T., Roden R.B., Wu T.C. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr. Opin. Investig. Drugs 2004, 5:1247-1261.
34. Tran N.P., Hung C.F., Roden R., Wu T.C. Control of HPV infection and related cancer through vaccination. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2014, 193:149-171.
35. Trottier H., Burchell A.N. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009, 12:291-307.
36. Wong S.B., Buck C.B., Shen X., Siliciano R.F. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J Immunol 2004, 173:3073-3083.
37. Zhang M., Ishii K., Hisaeda H., Murata S., Chiba T., Tanaka K., Li Y., Obata C., Furue M., Himeno K. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology 2004, 112:567-574.